Biography: Guilherme Attizzani, MD
- Director, Valve and Structural Heart Disease Center,Harrington Heart and Vascular Institute, University Hospitals
- Co-Director, Valve and Structural Heart Center, Harrington Heart and Vascular Institute, University Hospitals
- Director, Valve and Structural Heart Center, UH Cleveland Medical Center
- Professor, CWRU School of Medicine
Fellowship | Structural Heart Disease
Structural Heart Disease - Ferrarotto And Policlinico Hospitals (2013 - 2014)
Research Fellowship | Cardiovascular Imaging
Cardiovascular Imaging - Uh Case Medical Center (2010 - 2012)
Fellowship | Interventional Cardiology
Interventional Cardiology - Institute Dante Pazzanese Of Cardiology (2003 - 2007)
Residency | Internal Medicine
Internal Medicine - Hospital Sao Vicente De Paulo- Jundiai College Of Medicine (2001 - 2003)
Faculdade De Medicina De Jundiai (FMJ) (2000)
Guilherme Attizzani, MD, is a nationally and internationally recognized interventional cardiologist and heart valve specialist, serving as Co-Director of the Valve and Structural Heart Disease Center, and the Alexander and Marianna McAfee Chair in Innovative Cardiac Interventions with University Hospitals Harrington Heart & Vascular Institute. He is also a Professor of Medicine at Case Western Reserve University.
Dr. Attizzani completed cardiology training at Dante Pazzanese Institute, University in Sao Paulo, Brazil, which is the largest cardiology hospital in Latin America. He also completed two years of interventional cardiology training there and then moved to the United States for a three-year research fellowship in intravascular imaging.
Dr. Attizzani has become one of the world’s leading experts in intravascular optical coherence tomography (OCT). His research has helped improve stent implantation techniques, enabled a better understanding of vascular healing after drug-eluting stent implantation, and revealed important features of unstable coronary plaques. Dr. Attizzani published several scientific papers on OCT and was the editor of a book dedicated to this modality. He has also trained hundreds of physicians worldwide on OCT.
With the development of structural heart disease interventions, in particular the implantation of transcatheter heart valves, Dr. Attizzani sought specialized training in this growing field. He went to Italy to train for two years in a clinical fellowship devoted exclusively to valve and structural heart intervention at Ferrarotto Hospital, University of Catania, one of Europe’s largest volume centers for transcatheter valves.
Dr. Attizzani has become a world leader in optimal practices and minimally invasive approaches using local anesthesia only, for transcatheter aortic valve replacement, or TAVR. His extensive experience includes implantation and oversight of more than 3,000 transcatheter heart valves. He travels all over the world teaching physicians how to optimally implant these devices. In addition, his expertise has helped launch the use of transcatheter heart valve interventions in Argentina, Brazil, India, Japan and Taiwan, where he continues to proctor physicians.
Dr. Attizzani has received multiple clinical and academic honors. He is an avid researcher, authoring over 135 peer reviewed articles and leading 15 clinical trials. His areas of expertise include aortic valve stenosis, mitral valve regurgitation, transcatheter aortic valve replacement, and transcatheter mitral valve repair and replacement.
University Hospitals is committed to transparency in our interactions with industry partners, such as pharmaceutical, biotech, or medical device companies. At UH, we disclose practitioner and their family members’ ownership and intellectual property rights that are or in the process of being commercialized. In addition, we disclose payments to employed practitioners of $5,000 or more from companies with which the practitioners interact as part of their professional activities. These practitioner-industry relationships assist in developing new drugs, devices and therapies and in providing medical education aimed at improving quality of care and enhancing clinical outcomes. At the same time, UH understands that these relationships may create a conflict of interest. In providing this information, UH desires to assist patients in talking with their practitioners about industry relationships and how those relationships may impact their medical care.
UH practitioners seek advance approval for certain new industry relationships. In addition, practitioners report their industry relationships and activities, as well as those of their immediate family members, to the UH Office of Outside Interests annually. We review these reports and implement management plans, as appropriate, to address conflicts of interest that may arise in connection with medical research, clinical care and purchasing decisions.
View UH’s policy (PDF) on practitioner-industry relationships.
As of December 31, 2016, Guilherme Attizzani disclosed the following Outside Relationships with Industry:
- - Abbott Vascular - Consulting payments
- - Edwards Lifesciences - Consulting payments
- - Medtronic - Consulting payments
- - St Jude Medical, Inc - Consulting payments